Mantell Associates recently appointed Axel Schlueter as Business Development Director CDMO Europe at PharmaBlock. Axel is a seasoned Business Development and Key Account Manager with 20+ years of working experience in the Fine Chemicals Industry, 10 of those being stationed in China.
PharmaBlock Sciences (Nanjing), Inc. is a leading provider of innovative chemistry products & services throughout the pharmaceutical R&D process and commercial production. It’s core businesses include: a rationally designed building blocks (BBs) collection, supplying from discovery, to development & commercial; development & manufacturing of RSMs, intermediates & APIs for drug development & commercial.
Officially operated in 2008, PharmaBlock has rapidly gained recognition for its outstanding capabilities in the design, synthesis, & supply of novel BBs. It has generated a large and unique collection of high-quality and diverse BBs, which are increasingly adopted by drug hunters to enrich the structure options, improve compound quality, expand patent space and eventually accelerate drug discovery projects. Inspired by the BBs, it has established a powerful drug discovery platform for medicinal chemists to quickly identify hit/lead. The platform includes a set of efficient tools, including but not limited to FBDD, DELT, & Virtual Screening.
Company website – http://www.pharmablock.com
To find out more about PharmBlock, contact Robin Mantell on +44 (0)20 3854 7700 or robin.mantell@mantellassociates.com.